Clinical Trials · NCT00039962
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- SciClone Pharmaceuticals
- Enrollment
- 500
- Start date
- May 2002
- Locations
- 56 sites, United States, Puerto Rico
- Primary endpoint
- Study in Hepatitis C